Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

forbes.com - George Achilleos - Why Risk Mitigation Tools Are A Hard Sell In Pharma-And What Might Change That
Why Risk Mitigation Tools Are A Hard Sell In Pharma-And What Might Change That
Forbes –

George Achilleos is the CEO of NetraMark Holdings Inc. ​Drug development has a strange economic problem. A pharmaceutical company may be willing to spend tens or even hundreds of millions of dollars advancing a drug into a major clinical…

bloomberg.com - Angel Adegbesan - Adarx Pharma Shares Climb 30% After $446.3 Million Upsized IPO
Adarx Pharma Shares Climb 30% After $446.3 Million Upsized IPO
Bloomberg –

Adarx Pharmaceuticals Inc., a late-stage developer of gene therapies, jumped 30% after raising $446.3 million in an upsized initial public offering. Shares of the San Diego-based firm, which counts OrbiMed Advisors as a backer, opened at $22.10…

cnbc.com - Mike Sheen - Pharma stock soars 150% on injectables deal with Wegovy maker Novo
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
CNBC –

The Swedish drug-delivery company agreed to license its PharmaShell technology to Novo Nordisk for up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Novo Nordisk will use the technology to…

axios.com - Claire Rychlewski - AI risk raises the bar for outsourced pharma marketing deals
AI risk raises the bar for outsourced pharma marketing deals
Axios –

Axios Pro Exclusive Content 51 mins ago…

fool.com - Reuben Gregg Brewer - Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
The Motley Fool –

Revolution Medicines (RVMD +4.78%) just got some very good news: The FDA gave the company's RASONQUE breakthrough therapy designation. That could help speed the metastatic pancreatic cancer drug to market. But the stock is up 330% over the past…

dynamitenews.com - Rishira Jain - Kanpur Murder Twist: Rs 40 Lakh Debt, Property Dispute Put Pharma Dealer's Son Under Scanner | Dynamite News
Kanpur Murder Twist: Rs 40 Lakh Debt, Property Dispute Put Pharma Dealer's Son Under Scanner | Dynamite News
News: Today's News Headlines & Daily Updates from Sports, Movies, Politics, Business | Dynamite News –

Post Published By: Rishira Jain Updated: 25 September 2026, 3:38 PM IST Kanpur: A shocking twist has emerged in the murder case of Uttar Pradesh pharmaceutical businessman Vineet Manocha, with police claiming that the victim's own son allegedly…

thehindubusinessline.com - Natco Pharma board approves rights issue to raise up to ₹1,279 crore
Natco Pharma board approves rights issue to raise up to ₹1,279 crore
BusinessLine –

Drug maker Natco Pharma on Friday said its board of directors has approved the issuance of equity shares through a rights issue to raise up to ₹1,279.35 crore. According to a regulatory filing, the company will issue up to 1,70,58,082 equity…

thehindubusinessline.com - Nifty holds 23,000, Sensex up 44 pts; Axis Bank, Asian Paints gain as IT, Pharma drag
Nifty holds 23,000, Sensex up 44 pts; Axis Bank, Asian Paints gain as IT, Pharma drag
BusinessLine –

Markets were trading in a narrow range around midday on Friday, with the Nifty 50 at 23,051.50, down 11.60 points or 0.05 per cent, and the Sensex at 73,624.77, up 44.23 points or 0.06 per cent, as of 1.58 pm. The indices managed to hold above the…

marketbeat.com - Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
MarketBeat –

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence…

scmp.com - Xinmei Shen - How Chinese biotech is graduating from licensing deals to broader partnerships
How Chinese biotech is graduating from licensing deals to broader partnerships
South China Morning Post –

Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based…

globenewswire.com - CROSSJECT - CROSSJECT strengthens its governance for the industrial and commercial deployment phase
CROSSJECT strengthens its governance for the industrial and commercial deployment phase
GlobeNewswire –

The Executive Board is expanded to five members: Olivier Lacombe, Didier Morin and Lionel Seltz join Patrick Alexandre and Isabelle Liebschutz A leadership team covering the entire value chain: pharmaceutical development, industrial operations…

globenewswire.com - Orion Oyj - Orion Corporation: Acquisition of own shares during week 39, 2026
Orion Corporation: Acquisition of own shares during week 39, 2026
GlobeNewswire –

Orion Corporation: Acquisition of own shares during week 39, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than…

fool.com - Adria Cimino - Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
The Motley Fool –

Today, a very valuable market -- one heading toward $100 billion by the end of the decade -- is dominated by two pharma giants, Eli Lilly and Novo Nordisk. And this is the weight loss drug market. Lilly and Novo each sell GLP-1 drugs, products that…

wsj.com - David Wainer - The Peptide Boom That Isn't About Your Muscles
The Peptide Boom That Isn't About Your Muscles
Wall Street Journal –

Peptides are everywhere lately. Influencers inject them for muscle and recovery, and the Food and Drug Administration could soon allow these products to be sold by compounding pharmacies. While the marketing of these injections to biohackers and…

rediff.com - Rediff News - Sensex gains over 100 pts, Nifty hovers around 23,100
Sensex gains over 100 pts, Nifty hovers around 23,100
Rediff.com –

Indian equity markets recovered soon after opening in the red on Friday, extending Thursday's correction, to trade largely flat. The Sensex gained over 100 points, while the Nifty hovered around the 23,100 mark, with Nifty IT emerging as the…

Receive a Daily briefing on Pharma Industry News

Get Started